UY34999A - Formulaciones de anticuerpos anti-receptor de prolactina - Google Patents

Formulaciones de anticuerpos anti-receptor de prolactina

Info

Publication number
UY34999A
UY34999A UY0001034999A UY34999A UY34999A UY 34999 A UY34999 A UY 34999A UY 0001034999 A UY0001034999 A UY 0001034999A UY 34999 A UY34999 A UY 34999A UY 34999 A UY34999 A UY 34999A
Authority
UY
Uruguay
Prior art keywords
prolactin
formulations
receiver
antibodies anti
free
Prior art date
Application number
UY0001034999A
Other languages
English (en)
Inventor
Ma Xinghang
Xiang Jun
Niu Jianjie
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY34999A publication Critical patent/UY34999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Se proporcion an formulaciones de anticuerpos anti-receptor de prolactina de amplio intervalo de concentración, especialmente de alta concentración,sustancialmente sin sal que son sustancialmente isosmóticas y de baja viscosidad
UY0001034999A 2012-08-31 2013-08-30 Formulaciones de anticuerpos anti-receptor de prolactina UY34999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261695949P 2012-08-31 2012-08-31
US13/842,906 US8883979B2 (en) 2012-08-31 2013-03-15 Anti-prolactin receptor antibody formulations

Publications (1)

Publication Number Publication Date
UY34999A true UY34999A (es) 2014-03-31

Family

ID=49162240

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001034994A UY34994A (es) 2012-08-31 2013-08-29 Formulaciones de anticuerpo anti receptor de prolactina
UY0001034999A UY34999A (es) 2012-08-31 2013-08-30 Formulaciones de anticuerpos anti-receptor de prolactina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001034994A UY34994A (es) 2012-08-31 2013-08-29 Formulaciones de anticuerpo anti receptor de prolactina

Country Status (30)

Country Link
US (4) US8883979B2 (es)
EP (1) EP2890397B1 (es)
JP (1) JP6444871B2 (es)
KR (1) KR102100282B1 (es)
CN (3) CN104736175B (es)
AR (2) AR092387A1 (es)
AU (1) AU2013308907B2 (es)
BR (1) BR112015004397B1 (es)
CA (1) CA2883097C (es)
CY (1) CY1121990T1 (es)
DK (1) DK2890397T3 (es)
ES (1) ES2742868T3 (es)
HK (1) HK1207316A1 (es)
HR (1) HRP20191199T1 (es)
HU (1) HUE045494T2 (es)
IL (1) IL237277B (es)
IN (1) IN2015DN02255A (es)
LT (1) LT2890397T (es)
MX (1) MX367691B (es)
NZ (1) NZ705178A (es)
PL (1) PL2890397T3 (es)
PT (1) PT2890397T (es)
RS (1) RS59207B1 (es)
RU (1) RU2649372C2 (es)
SG (1) SG11201501225SA (es)
SI (1) SI2890397T1 (es)
TW (3) TW201422235A (es)
UY (2) UY34994A (es)
WO (1) WO2014036076A1 (es)
ZA (1) ZA201501279B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2825553B1 (en) 2012-03-14 2018-07-25 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
PL2935331T3 (pl) 2012-12-24 2018-07-31 Abbvie Inc. Białka wiążące receptor prolaktyny i ich zastosowania
TW201513882A (zh) * 2013-03-15 2015-04-16 Bayer Healthcare Llc 抗－催乳激素受體抗體調配物
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
AR103173A1 (es) * 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
SG11201705484WA (en) * 2015-02-09 2017-08-30 Ucb Biopharma Sprl Pharmaceutical formulation
EA038973B1 (ru) 2015-07-06 2021-11-17 Ридженерон Фармасьютикалз, Инк. Полиспецифические антигенсвязывающие молекулы и их применения
RS64263B1 (sr) 2015-08-19 2023-07-31 Astrazeneca Ab Stabilna anti-ifnar1 formulacija
WO2017057644A1 (ja) * 2015-09-30 2017-04-06 持田製薬株式会社 高濃度抗体含有液体製剤
US11352446B2 (en) 2016-04-28 2022-06-07 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
GB201608323D0 (en) 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JPWO2018179138A1 (ja) * 2017-03-29 2020-02-06 持田製薬株式会社 抗体含有液体製剤
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP7398958B2 (ja) 2017-04-11 2023-12-15 キニクサ ファーマシューティカルズ， リミテッド 安定的抗ｏｓｍｒ抗体製剤
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN110799545A (zh) 2017-07-10 2020-02-14 拜耳制药股份公司 用于男性和女性模式脱发的催乳素受体抗体
KR20200089282A (ko) * 2017-11-20 2020-07-24 저스트-에보텍 바이오로직스, 아이엔씨. 등장화제로서 라이신 염을 함유하는 아플리베르셉트 제제 및 그것의 용도
WO2019157224A1 (en) 2018-02-07 2019-08-15 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2020053321A1 (en) * 2018-09-13 2020-03-19 F. Hoffmann-La Roche Ag Csf-1r antibody formulation
CA3115708A1 (en) * 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
CA3118282A1 (en) * 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
AU2020225202B2 (en) 2019-02-18 2023-10-26 Eli Lilly And Company Therapeutic antibody formulation
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023230532A1 (en) * 2022-05-26 2023-11-30 Compugen Ltd. Anti-tigit antibody formulation

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO1998056418A1 (en) 1997-06-13 1998-12-17 Genentech, Inc. Stabilized antibody formulation
AU2444899A (en) 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
CA2386228A1 (en) 1999-10-04 2001-04-12 Chiron Corporation Stabilized liquid pharmaceutical compositions comprising tissue factor pathway inhibitor (tfpi) polypeptides
GB0113179D0 (en) 2001-05-31 2001-07-25 Novartis Ag Organic compounds
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
SI1507556T1 (sl) 2002-05-02 2016-10-28 Wyeth Holdings Llc Konjugati kaliheamicinski derivat-nosilec
PT2283856T (pt) 2002-06-21 2017-12-26 Novo Nordisk Healthcare Ag Composições sólidas estabilizadas de polipéptidos do fator viia
CN1751236A (zh) * 2002-12-16 2006-03-22 健泰科生物技术公司 表达人cd20的转基因小鼠
KR20050110628A (ko) 2003-02-10 2005-11-23 엘란 파마슈티칼스, 인크. 면역글로불린 제제 및 이의 제조방법
EP3103869A1 (en) 2003-03-18 2016-12-14 Novo Nordisk Health Care AG Method for the production of factor vii polypeptides
AU2004222625A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor VII polypeptides
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
PL2335725T3 (pl) 2003-04-04 2017-04-28 Genentech, Inc. Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MX369959B (es) 2003-05-14 2019-11-27 Immunogen Inc Composicion de farmaco conjugado.
CA2525224A1 (en) 2003-05-23 2004-12-02 Michael Bech Jensen Protein stabilization in solution
EP1641487B1 (en) 2003-06-25 2012-02-29 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
ATE446768T1 (de) 2003-07-01 2009-11-15 Novo Nordisk Healthcare Ag Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden
BRPI0413518A (pt) 2003-08-14 2006-10-10 Novo Nordisk Healthcare Ag composição farmacêutica lìquida aquosa, método para preparar e uso da mesma, método para tratar uma sìndrome responsiva ao fator vii, e, recipiente hermético
WO2005033143A1 (ja) 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
DE10361599A1 (de) 2003-12-24 2005-07-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Flüssigformulierung von Antikörperkonjugaten
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
DE102004022927A1 (de) 2004-05-10 2005-12-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten
US20070196364A1 (en) 2004-07-27 2007-08-23 Human Genome Sciences, Inc. Pharmaceutical Formulation and Process
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008519032A (ja) * 2004-11-03 2008-06-05 キュラジェン コーポレイション Ｆｇｆ−２０の調合物、生成方法および使用
DE102005002353A1 (de) * 2005-01-18 2006-07-27 Abbott Gmbh & Co. Kg AGER-Rezeptor Multimerisierungs Epitope
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
AU2006261920A1 (en) * 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
EP1912667B1 (en) 2005-07-22 2012-08-29 Amgen Inc. Concentrated protein lyophilates, methods, and uses
US7422899B2 (en) * 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
EP1977763A4 (en) 2005-12-28 2010-06-02 Chugai Pharmaceutical Co Ltd STABILIZER PREPARATION CONTAINING ANTIBODIES
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
EP1988922A4 (en) 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
CN101495136A (zh) 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CL2007002412A1 (es) * 2006-08-18 2008-06-20 Novartis Ag Xoma Technology Lt Anticuerpo especifico para el dominio extracelular del receptor de prolactina (prlr); molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que la comprenden; metodo de produccion; composicion farmaceutica que comprende al
EP2066350A4 (en) 2006-09-25 2010-04-07 Medimmune Llc STABILIZED ANTIBODY FORMULATIONS AND THEIR USES
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
CA2672902C (en) 2006-12-21 2012-11-27 Amgen Inc. Formulations
EP2099475B1 (en) 2007-01-03 2016-08-24 Novo Nordisk Health Care AG Subcutaneous administration of coagulation factor viia-related polypeptides
CN101674847A (zh) 2007-05-02 2010-03-17 弗·哈夫曼-拉罗切有限公司 稳定蛋白质的方法
JP2010532790A (ja) 2007-07-06 2010-10-14 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗体処方
MX2010001723A (es) 2007-08-17 2010-04-30 Amgen Inc Formulaciones de anticuerpos y moleculas de fusion-fc usando policationes.
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20190045414A (ko) 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
AU2008339984A1 (en) * 2007-12-21 2009-07-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2009080541A1 (en) * 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Antibody formulation
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
JP2011510043A (ja) 2008-01-23 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 新規血液凝固因子インヒビター
CA2742988A1 (en) 2008-11-17 2010-05-20 Genentech, Inc. Method and formulation for reducing aggregation of a macromolecule under physiological conditions
CN104398471A (zh) * 2008-11-28 2015-03-11 Abbvie公司 稳定的抗体组合物和用于稳定其的方法
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CN102458469B (zh) * 2009-05-04 2014-12-24 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
EP3409289B1 (en) 2010-02-26 2020-09-30 Novo Nordisk A/S Stable antibody containing compositions
EA034617B1 (ru) * 2010-10-06 2020-02-27 Ридженерон Фармасьютикалз, Инк. Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r)

Also Published As

Publication number Publication date
HUE045494T2 (hu) 2019-12-30
DK2890397T3 (da) 2019-08-05
LT2890397T (lt) 2019-09-25
CA2883097C (en) 2022-11-15
EP2890397A1 (en) 2015-07-08
US8883979B2 (en) 2014-11-11
BR112015004397B1 (pt) 2022-07-19
PT2890397T (pt) 2019-09-10
JP2015528465A (ja) 2015-09-28
CY1121990T1 (el) 2020-10-14
UY34994A (es) 2014-03-31
BR112015004397A2 (pt) 2017-12-19
CN104736175A (zh) 2015-06-24
AU2013308907B2 (en) 2018-04-19
IN2015DN02255A (es) 2015-08-21
JP6444871B2 (ja) 2018-12-26
SG11201501225SA (en) 2015-03-30
ZA201501279B (en) 2016-11-30
ES2742868T3 (es) 2020-02-17
WO2014036076A1 (en) 2014-03-06
SI2890397T1 (sl) 2019-11-29
KR102100282B1 (ko) 2020-04-13
IL237277A0 (en) 2015-04-30
RU2015111319A (ru) 2016-10-20
TWI641384B (zh) 2018-11-21
TW201821103A (zh) 2018-06-16
NZ705178A (en) 2018-06-29
CN111202843A (zh) 2020-05-29
AR092401A1 (es) 2015-04-22
AU2013308907A1 (en) 2015-03-12
US20150252116A1 (en) 2015-09-10
CA2883097A1 (en) 2014-03-06
HK1207316A1 (en) 2016-01-29
TW201422235A (zh) 2014-06-16
TW201414491A (zh) 2014-04-16
AR092387A1 (es) 2015-04-22
TWI688404B (zh) 2020-03-21
MX2015002412A (es) 2015-09-29
US20150093393A1 (en) 2015-04-02
US20140065158A1 (en) 2014-03-06
KR20150046298A (ko) 2015-04-29
EP2890397B1 (en) 2019-06-19
PL2890397T3 (pl) 2019-12-31
US20170008965A1 (en) 2017-01-12
HRP20191199T1 (hr) 2019-10-18
CN104736175B (zh) 2019-11-01
MX367691B (es) 2019-09-02
RU2649372C2 (ru) 2018-04-02
RS59207B1 (sr) 2019-10-31
CN111202844A (zh) 2020-05-29
IL237277B (en) 2020-04-30

Similar Documents

Publication Publication Date Title
UY34999A (es) Formulaciones de anticuerpos anti-receptor de prolactina
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
CL2018000479A1 (es) Linfoopeitina strimal tomica (tslp) - anticuerpos de union y metodos de uso de los anticuerpos
EA201592213A1 (ru) Антитела антирецептор трансферрина и способы их использования
CL2015002357A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos
UY35460A (es) Formulaciones de anticuerpos anti-receptor de prolactina
BR112017011932A2 (pt) ?anticorpos direcionados a receptor acoplado a proteína g e métodos de uso?
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CR20150329A (es) Inmunoglobulinas heterodiméricas
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
CL2016001432A1 (es) Nuevos anticuerpos anti-dpep3 y métodos de uso
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
BR112015018851A2 (pt) anticorpos cd47 de não depleção de plaquetas e de não depleção de células vermelhas do sangue, e métodos de uso dos mesmos
UY34815A (es) Anticuerpos biespecíficos y sus métodos de uso
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
MX2014014376A (es) Anticuerpos de anti-biotina y metodos de uso.
CR20150668A (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
ECSP13012536A (es) Composiciones de anticuerpo y métodos de uso
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
MX2014014381A (es) Anticuerpos de anti-teofilina y metodos de uso.
MA43464B1 (fr) Anticorps anti-cd3 et méthodes d'utilisation

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20220614